Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary - As cancer rates climb ...

A pairing of two experimental drugs inhibits tumor growth and blocks drug-induced resistance in ovarian cancer, according to a preclinical study led by Weill Cornell Medicine investigators. The ...

Prince William and Princess Kate made a stunning return to the spotlight after nearly a month of separation amid her ...

Prince William will permanently sideline Prince Andrew once he takes the throne, marking a clear break from the past.As King ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

The Netherlands’ three population screenings for cervical cancer, breast cancer, and colon cancer save the lives of thousands ...

The Phase II trial will compare progression-free survival in lung cancer patients treated according to their molecular subtypes.

A letter to Bosnia and Herzegovina announcing a 30 percent tariff rate starting on August 1 was mistakenly addressed to “Mr.

While the growing oncology pipeline offers tremendous potential, the path from clinical development through to commercial ...

A State Department cable revealed how an imposter contacted several officials while pretending to be the secretary of state.

The PALMARES-2 trial reveals that abemaciclib and ribociclib outperform palbociclib in real-world progression-free survival for advanced breast cancer patients.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...